CRISPR/Cas9 for cancer treatment: technology, clinical applications and challenges

Clustered regularly interspaced short palindromic repeats (CRISPR) is described as RNA mediated adaptive immune system defense, which is naturally found in bacteria and archaea. CRISPR-Cas9 has shown great promise for cancer treatment in cancer immunotherapy, manipulation of cancer genome and epigen...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Briefings in functional genomics 2020-05, Vol.19 (3), p.209-214
Hauptverfasser: Cheng, Xing, Fan, Shaoyi, Wen, Chengcai, Du, Xianfa
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 214
container_issue 3
container_start_page 209
container_title Briefings in functional genomics
container_volume 19
creator Cheng, Xing
Fan, Shaoyi
Wen, Chengcai
Du, Xianfa
description Clustered regularly interspaced short palindromic repeats (CRISPR) is described as RNA mediated adaptive immune system defense, which is naturally found in bacteria and archaea. CRISPR-Cas9 has shown great promise for cancer treatment in cancer immunotherapy, manipulation of cancer genome and epigenome and elimination or inactivation of carcinogenic viral infections. However, many challenges remain to be addressed to increase its efficacy, including off-target effects, editing efficiency, fitness of edited cells, immune response and delivery methods. Here, we explain CRISPR-Cas classification and its general function mechanism for gene editing. Then, we summarize these preclinical CRISPR-Cas9-based therapeutic strategies against cancer. Moreover, the challenges and improvements of CRISPR-Cas9 clinical applications will be discussed.
doi_str_mv 10.1093/bfgp/elaa001
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_bfgp_elaa001</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>32052006</sourcerecordid><originalsourceid>FETCH-LOGICAL-c329t-28c1c100fb20d4b16da271c62fa13420a06515a7b22806259e516fe298cbd8673</originalsourceid><addsrcrecordid>eNpNkLFOwzAURS0EolXpxoz8AQ19z06chA1FFCpVAhWYoxfHboNcJ4rD0L-nVQviLvcOR3c4jN0i3CPkcl7ZTTc3jggAL9hYQIyRUEl6-W-P2DSELzhEYhwjXLORFJAIADVm62K9fH9bzwsKObdtzzV5bXo-9IaGnfHDAx-M3vrWtZv9jGvX-EaT49R17jCGpvWBk6-53pJzxm9MuGFXllww03NP2Ofi6aN4iVavz8vicRVpKfIhEplGjQC2ElDHFaqaRIpaCUsoYwEEKsGE0kqIDJRIcpOgskbkma7qTKVywmanX923IfTGll3f7Kjflwjl0U55tFOe7RzwuxPefVc7U__Bvy7kD5DzYF4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>CRISPR/Cas9 for cancer treatment: technology, clinical applications and challenges</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Cheng, Xing ; Fan, Shaoyi ; Wen, Chengcai ; Du, Xianfa</creator><creatorcontrib>Cheng, Xing ; Fan, Shaoyi ; Wen, Chengcai ; Du, Xianfa</creatorcontrib><description>Clustered regularly interspaced short palindromic repeats (CRISPR) is described as RNA mediated adaptive immune system defense, which is naturally found in bacteria and archaea. CRISPR-Cas9 has shown great promise for cancer treatment in cancer immunotherapy, manipulation of cancer genome and epigenome and elimination or inactivation of carcinogenic viral infections. However, many challenges remain to be addressed to increase its efficacy, including off-target effects, editing efficiency, fitness of edited cells, immune response and delivery methods. Here, we explain CRISPR-Cas classification and its general function mechanism for gene editing. Then, we summarize these preclinical CRISPR-Cas9-based therapeutic strategies against cancer. Moreover, the challenges and improvements of CRISPR-Cas9 clinical applications will be discussed.</description><identifier>ISSN: 2041-2657</identifier><identifier>EISSN: 2041-2657</identifier><identifier>DOI: 10.1093/bfgp/elaa001</identifier><identifier>PMID: 32052006</identifier><language>eng</language><publisher>England</publisher><ispartof>Briefings in functional genomics, 2020-05, Vol.19 (3), p.209-214</ispartof><rights>The Author(s) 2020. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c329t-28c1c100fb20d4b16da271c62fa13420a06515a7b22806259e516fe298cbd8673</citedby><cites>FETCH-LOGICAL-c329t-28c1c100fb20d4b16da271c62fa13420a06515a7b22806259e516fe298cbd8673</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32052006$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cheng, Xing</creatorcontrib><creatorcontrib>Fan, Shaoyi</creatorcontrib><creatorcontrib>Wen, Chengcai</creatorcontrib><creatorcontrib>Du, Xianfa</creatorcontrib><title>CRISPR/Cas9 for cancer treatment: technology, clinical applications and challenges</title><title>Briefings in functional genomics</title><addtitle>Brief Funct Genomics</addtitle><description>Clustered regularly interspaced short palindromic repeats (CRISPR) is described as RNA mediated adaptive immune system defense, which is naturally found in bacteria and archaea. CRISPR-Cas9 has shown great promise for cancer treatment in cancer immunotherapy, manipulation of cancer genome and epigenome and elimination or inactivation of carcinogenic viral infections. However, many challenges remain to be addressed to increase its efficacy, including off-target effects, editing efficiency, fitness of edited cells, immune response and delivery methods. Here, we explain CRISPR-Cas classification and its general function mechanism for gene editing. Then, we summarize these preclinical CRISPR-Cas9-based therapeutic strategies against cancer. Moreover, the challenges and improvements of CRISPR-Cas9 clinical applications will be discussed.</description><issn>2041-2657</issn><issn>2041-2657</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNpNkLFOwzAURS0EolXpxoz8AQ19z06chA1FFCpVAhWYoxfHboNcJ4rD0L-nVQviLvcOR3c4jN0i3CPkcl7ZTTc3jggAL9hYQIyRUEl6-W-P2DSELzhEYhwjXLORFJAIADVm62K9fH9bzwsKObdtzzV5bXo-9IaGnfHDAx-M3vrWtZv9jGvX-EaT49R17jCGpvWBk6-53pJzxm9MuGFXllww03NP2Ofi6aN4iVavz8vicRVpKfIhEplGjQC2ElDHFaqaRIpaCUsoYwEEKsGE0kqIDJRIcpOgskbkma7qTKVywmanX923IfTGll3f7Kjflwjl0U55tFOe7RzwuxPefVc7U__Bvy7kD5DzYF4</recordid><startdate>20200520</startdate><enddate>20200520</enddate><creator>Cheng, Xing</creator><creator>Fan, Shaoyi</creator><creator>Wen, Chengcai</creator><creator>Du, Xianfa</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20200520</creationdate><title>CRISPR/Cas9 for cancer treatment: technology, clinical applications and challenges</title><author>Cheng, Xing ; Fan, Shaoyi ; Wen, Chengcai ; Du, Xianfa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c329t-28c1c100fb20d4b16da271c62fa13420a06515a7b22806259e516fe298cbd8673</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Cheng, Xing</creatorcontrib><creatorcontrib>Fan, Shaoyi</creatorcontrib><creatorcontrib>Wen, Chengcai</creatorcontrib><creatorcontrib>Du, Xianfa</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Briefings in functional genomics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cheng, Xing</au><au>Fan, Shaoyi</au><au>Wen, Chengcai</au><au>Du, Xianfa</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CRISPR/Cas9 for cancer treatment: technology, clinical applications and challenges</atitle><jtitle>Briefings in functional genomics</jtitle><addtitle>Brief Funct Genomics</addtitle><date>2020-05-20</date><risdate>2020</risdate><volume>19</volume><issue>3</issue><spage>209</spage><epage>214</epage><pages>209-214</pages><issn>2041-2657</issn><eissn>2041-2657</eissn><abstract>Clustered regularly interspaced short palindromic repeats (CRISPR) is described as RNA mediated adaptive immune system defense, which is naturally found in bacteria and archaea. CRISPR-Cas9 has shown great promise for cancer treatment in cancer immunotherapy, manipulation of cancer genome and epigenome and elimination or inactivation of carcinogenic viral infections. However, many challenges remain to be addressed to increase its efficacy, including off-target effects, editing efficiency, fitness of edited cells, immune response and delivery methods. Here, we explain CRISPR-Cas classification and its general function mechanism for gene editing. Then, we summarize these preclinical CRISPR-Cas9-based therapeutic strategies against cancer. Moreover, the challenges and improvements of CRISPR-Cas9 clinical applications will be discussed.</abstract><cop>England</cop><pmid>32052006</pmid><doi>10.1093/bfgp/elaa001</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2041-2657
ispartof Briefings in functional genomics, 2020-05, Vol.19 (3), p.209-214
issn 2041-2657
2041-2657
language eng
recordid cdi_crossref_primary_10_1093_bfgp_elaa001
source EZB-FREE-00999 freely available EZB journals; PubMed Central
title CRISPR/Cas9 for cancer treatment: technology, clinical applications and challenges
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T00%3A12%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CRISPR/Cas9%20for%20cancer%20treatment:%20technology,%20clinical%20applications%20and%20challenges&rft.jtitle=Briefings%20in%20functional%20genomics&rft.au=Cheng,%20Xing&rft.date=2020-05-20&rft.volume=19&rft.issue=3&rft.spage=209&rft.epage=214&rft.pages=209-214&rft.issn=2041-2657&rft.eissn=2041-2657&rft_id=info:doi/10.1093/bfgp/elaa001&rft_dat=%3Cpubmed_cross%3E32052006%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/32052006&rfr_iscdi=true